A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Norway- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Groenland 32, 3045 Drammen, Norway
Vestre Viken HF in Drammen, Norway specialises in clinical trials of conditions such as Non-small cell lung cancer, Amyotrophic lateral sclerosis, Arteriosclerosis, Malignant melanoma, and other specialisations. This site conducts important research.
At Vestre Viken HF, the Department of oncology is conducting a large body of research in neoplasms, with a major focus on non-small cell lung cancer and other advanced lung tumors. These studies are designed to test new treatment combinations, improve outcomes after standard therapy, and better define which patients may benefit most from targeted and immune-based approaches.
This research includes efforts to refine cancer care through precision medicine, evaluate combinations with pembrolizumab and other modern agents, and support better disease control in difficult-to-treat cancers.
The site is also active in breast cancer research, especially for HER2-positive and estrogen receptor-positive disease. The trials aim to improve the effectiveness of treatment before surgery, extend disease control in advanced cancer, and compare new targeted strategies with established care.
Research in this area reflects a strong interest in matching therapy to tumor biology, with the goal of improving response rates and long-term outcomes for patients with breast cancer.
Clinical trials at the site cover several immune system diseases and chronic inflammatory conditions, including multiple sclerosis, Crohn's disease, and juvenile idiopathic arthritis. These studies are focused on finding better ways to control disease activity, reduce flares, and improve day-to-day function for patients living with long-term immune-related disorders.
The research also includes efforts to compare existing therapies with newer options, helping build clearer evidence for safer and more effective management of chronic inflammatory disease.
Another important area of work involves cardiovascular diseases, nutritional and metabolic diseases, and kidney-related complications. Trials here address heart failure, hypertension, obesity, and cardiovascular risk in patients with advanced kidney disease, with the aim of improving prevention and treatment of serious complications.
These studies help clarify how newer therapies may lower inflammation, improve heart function, and reduce hospitalizations in patients with complex chronic disease.
The research portfolio also includes studies in nervous system diseases and eye diseases. Key topics include amyotrophic lateral sclerosis, acute ischemic stroke, and central retinal artery occlusion, with trials aimed at improving recovery, slowing disease progression, and expanding treatment options in urgent and high-impact conditions.
This work reflects a broader effort at Vestre Viken HF to advance care in conditions where faster diagnosis and more effective treatment can make a major difference.
The site conducts trials across respiratory tract diseases, virus diseases, and selected analytical, diagnostic and therapeutic techniques. Studies include COVID-19, COPD, and other respiratory infections, as well as research in surgical care aimed at improving recovery and reducing complications.
Together, these studies are designed to test better treatment strategies, support safer care, and improve outcomes in both acute illness and perioperative settings.
Clinical trials currently enrolling participants at this site.
NorwayPhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
NorwayStudy of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease
NorwayStudy on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)
NorwayStudy on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis
NorwayStudy of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
NorwayFirst‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma
NorwayPumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
NorwayTesting MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment
NorwayStudy of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer
NorwayComparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis
NorwayStudy on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure
NorwayMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.